Kronos Bio, Inc. (KRON)

USD 0.95

(-0.66%)

Market Cap (In USD)

57.32 Million

Revenue (In USD)

6.28 Million

Net Income (In USD)

-112.67 Million

Avg. Volume

150.64 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.69-1.6
PE
-
EPS
-
Beta Value
1.864
ISIN
US50107A1043
CUSIP
50107A104
CIK
1741830
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Norbert W. Bischofberger Ph.D.
Employee Count
-
Website
https://kronosbio.com
Ipo Date
2020-10-09
Details
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.